Transcript Slide 1
Up, Up, and Away? Trends in Chlamydial Infections in the U.S. Steven Shapiro Catherine Lindsey Satterwhite, MSPH, MPH Division of STD Prevention Centers for Disease Control and Prevention June, 2008 Disclaimer: The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention. Outline... 2006 Chlamydia Supplement Whoops. National Chlamydia Data Sequelae Chlamydia Screening Coverage Region I Chlamydia IPP Data 2006 Chlamydia Supplement They’re Gone!! Warehouse ran out of stock in early April Even after triple checking... >1000 excess orders Syphilis supplements also gone The ‘Whoops’ Part Figure 10 in the 2006 CT supplement was INCORRECT See Figure K in overall 2006 Surveillance Report for correct prevalence rates Calculations based on gonorrhea, not chlamydia Errata will be sent out this week (Thanks, Canada!) National Chlamydia Data Interpretation Challenges Increases in lab test sensitivity Underdetection, underreporting 2000 estimate: 2.8 million cases 2000 case reports: 709,452 Different screening rates Application of screening criteria varies CDC: Screen all sexually-active women <26 years annually Median State-specific Chlamydia Prevalence by Year: Women Entering the National Job Training Program, 1998-2006 Prevalence (%)) 18 16 14 12 10 8 6 Test type change (mid-2005): 2005: 27% NAAT 2006: 89% NAAT 4 2 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 Year Testing Trends by Year: Women Entering the National Job Training Program, 2000-2006 100 90 80 % of All Tests 70 60 GP PACE 2 50 BD ProbeTec (urine) BD ProbeTec (cervix) 40 30 20 10 0 2000 2001 2002 2003 2004 2005 2006 *From 1997-1999, Gen-Probe (GP) PACE 2 tests were used. 18 16 14 12 10 8 6 4 2 0 GP PACE 2 BD ProbeTec (urine) Year 2006 2005 2004 2003 2002 2001 2000 1999 1998 BD ProbeTec (cervix) 1997 Prevalence (%) Median State-specific Chlamydia Prevalence by Year by Test Type: Women Entering the National Job Training Program, 1997-2006 National Morbidity Data (Case Reports) Chlamydia — Rates by Sex: United States, 1987–2006 Rate (per 100,000 population) 600 Men Women Total 480 360 527.5* 515.8 ↓ Program expansion CT screening demonstration project (Region X) 183.0* 173.0 240 ↓ 120 0 1987 89 91 93 95 Notifiable 97 99 2001 03 All 50 report Total cases reported in 2006: 1,030,911 * 2007 data are preliminary (as of February 16, 2008). 1,073,699* 05 Chlamydia — Rates by Race/Ethnicity: United States, 1997–2006 Rate (per 100,000 population) 1700 American Indian/AK Native Asian/Pacific Islander Black Hispanic White 1360 1275.0 ↓ 1020 680 340 153.1 0 1997 98 99 2000 01 02 03 04 05 06 Chlamydia – Rates by Race and Sex: United States 2001-2006 2000 1800 1600 1400 1200 1000 800 600 400 200 0 1760.9 741.2 237.0 66.0 2001 White women 2002 2003 White men 2004 2005 Black women 2006 Black men Chlamydia — Age- and Sex-specific Rates: United States, 2006 Men Rate (per 100,000 population) 3000 2400 1800 1200 600 0 11.6 545.1 Age 10-14 0 Women 600 1200 1800 2400 3000 121.5 15-19 856.9 2862.7 20-24 480.8 2797.0 25-29 222.2 1141.2 30-34 415.7 120.8 35-39 174.2 65.1 40-44 27.8 45-54 25.6 9.1 55-64 6.8 2.8 65+ 2.2 173.4 Total 69.0 517.0 Chlamydia — Cases by Reporting Source and Sex: United States, 1997–2006 Cases (in thousands) 750 600 non-STD Clinic Male non-STD Clinic Female STD Clinic Male STD Clinic Female 450 300 150 0 1997 98 99 2000 01 02 03 04 05 06 IPP Data Reported Chlamydia Test* Volume: Infertility Prevention Program, 2001 - 2006 3,500,000 3,000,000 2,500,000 2,000,000 1,500,000 1,000,000 500,000 0 2001 2002 2003 2004 *Positive and negative test results only. 2005 2006 Proportion of reported chlamydia tests* occurring among women aged 15-24 years attending family planning clinics that were NAATs, by region, IPP 2006 100 90 80 70 60 50 40 30 20 10 0 I II III IV *Positive and negative results only. V VI VII VIII IX X Chlamydia — Trends in positivity among 15- to 24-year-old women tested in family planning clinics by HHS region, 2002–2006 6.7 7.5 7.7 7.4 7.5 8.2 8.7 8.8 9.0 9.2 02 03 04 05 06 02 03 04 05 06 02 03 04 05 06 Region X Region V Region I 8.0 8.5 8.5 8.1 8.6 9.1 10.2 9.7 7.8 7.5 X 02 03 04 05 06 IX II I V VIII Region IX III VII 7.4 7.3 7.6 7.4 8.4 02 03 04 05 06 6.1 5.5 5.4 5.5 5.5 VI Region VIII IV 02 03 04 05 06 Region II 6.8 6.9 7.5 7.4 6.7 02 03 04 05 06 Region III 11.8 11.7 11.7 11.5 11.3 10.1 9.6 10.9 11.0 11.0 02 03 04 05 06 02 03 04 05 06 02 03 04 05 06 Region VII Region VI Region IV 6.5 6.5 6.8 6.8 7.6 Note: Trends adjusted for changes in laboratory test method and associated increases in test sensitivity. SOURCE: Regional Infertility Prevention Projects; Office of Population Affairs; Local and State STD Control Programs; Centers for Disease Control and Prevention Chlamydia — Median State-specific Positivity Among 15-24 Year-old Women Tested in Family Planning Clinics, 1997–2006 Median state-specific positivity rate 10 6.7% ↓ 8 6 4 5.1% ↓ (2.8-16.9) (2.0-11.2) 2 0 1997 98 99 2000 01 02 03 04 05 Note: As of 1997, all 10 Health and Human Services (HHS) regions, representing all 50 states, the District of Columbia, and outlying areas, reported chlamydia positivity data. SOURCE: Regional Infertility Prevention Projects; Office of Population Affairs; Local and State STD Control Programs; Centers for Disease Control and Prevention 06 Other Data Chlamydia Prevalence Among Women and Men Aged 14-39 Years by Race/Ethnicity (NHANES), 1999-2002 Prevalence (%)x 10 7.2 8 5.3 6 4 2 3.1 1.5 3.1 1.5 0 Females Males Source: Datta, Annals 2007. NHANES=National Health and Nutrition Examination Survey Non-Hispanic White Non-Hispanic Black Mexican-American Chlamydia Positivity by Age, Adult Jails, 2006 Men 20 Positivity 16 12 8 4 0 Age 10.3 <20 9.8 20-24 0 4 8 2.5 >=35 Total 16 15.0 10.3 30-34 5.0 12 20 19.1 25-29 6.7 7.5 Women 6.2 3.8 9.3 Note: Percent positivity is presented from facilities reporting > 100 test results. Sequelae What’s happened with PID? Pelvic Inflammatory Disease — Hospitalizations of Women 15 to 44 Years of Age: United States, 1996–2005 Hospitalizations (in thousands) 75 60 45 Acute, Unspec. Chronic 30 15 0 1996 97 98 99 2000 01 02 03 04 Note: The relative standard error for these estimates of the total number of acute unspecified PID cases ranges from 8% to 11%. The relative standard error for these estimates of the total number of chronic PID cases ranges from 11% to 18%. Data only available through 2005. SOURCE: National Hospital Discharge Survey (National Center for Health Statistics, CDC) 05 Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985-2001* Hospital Discharges: PID * Sutton, STD, 2005 Ambulatory visits: PID Pelvic Inflammatory Disease — Initial Visits to Physicians’ Offices by Women 15 to 44 Years of Age: United States, 1997–2006 Visits (in thousands) 300 240 180 120 60 0 1997 98 99 2000 01 02 03 04 Note: The relative standard error for these estimates ranges from 19% to 30%. SOURCE: National Disease and Therapeutic Index (IMS Health) 05 06 Trends in 12-month infertility among married women, aged 15-44, 1965-2002* * Stephen, Fertility and Sterility, 2006 Chlamydia Screening Coverage Percent . HEDIS: Mean Chlamydia Screening Rates Females, Aged 16-20 Years 100 90 80 70 60 50 40 30 20 10 0 2000 2001 2002 2003 2004 2005 2006 Commercial Medicaid Cervical Cancer Screening 100.0 90.0 80.0 81.8 78.1 70.0 65.2 60.0 50.0 59.9 40.0 30.0 20.0 Commercial 10.0 Medicaid 0.0 2000 2001 2002 2003 2004 2005 Regional IPP Data Chlamydia — Trends in positivity among 15- to 24-year-old women tested in family planning clinics by HHS region, 2002–2006 6.7 7.5 7.7 7.4 7.5 8.2 8.7 8.8 9.0 9.2 02 03 04 05 06 02 03 04 05 06 02 03 04 05 06 Region X Region V Region I 8.0 8.5 8.5 8.1 8.6 9.1 10.2 9.7 7.8 7.5 X 02 03 04 05 06 IX II I V VIII Region IX III VII 7.4 7.3 7.6 7.4 8.4 02 03 04 05 06 6.1 5.5 5.4 5.5 5.5 VI Region VIII IV 02 03 04 05 06 Region II 6.8 6.9 7.5 7.4 6.7 02 03 04 05 06 Region III 11.8 11.7 11.7 11.5 11.3 10.1 9.6 10.9 11.0 11.0 02 03 04 05 06 02 03 04 05 06 02 03 04 05 06 Region VII Region VI Region IV 6.5 6.5 6.8 6.8 7.6 Note: Trends adjusted for changes in laboratory test method and associated increases in test sensitivity. SOURCE: Regional Infertility Prevention Projects; Office of Population Affairs; Local and State STD Control Programs; Centers for Disease Control and Prevention Region IV – Chlamydia positivity in 15-24 year old women in family planning clinics, 1997-2006 P ercent P ositive 15 12.7 11.7 11.2 10.5 10.4 10 10.1 10.9 11.0 11.0 04 05 06 9.6 5 0 97 98 99 00 01 U nadjusted 02 03 A djusted Region IV – Chlamydia positivity in 15-24 year old women in family planning clinics, 1997-2006 16 100 14 80 10 60 8 40 6 4 20 2 0 0 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 NAAT Usage Adjusted Unadjusted NAAT Proportion Percent Positive 12 How best to analyze programmatic data for surveillance purposes? Continuously Reporting Clinics? Program necessitates shifting funds Political considerations Continous clinics Stable, defined characteristics Additional information about clinic practice Region I* Clinic Participation Clinic Type 2002 2003 2004 2005 2006 Family Planning 90 94 113 109 96 STD 17 13 12 10 11 Adult Corrections 4 4 4 3 3 Juvenile Corrections 5 10 11 12 9 Other 18 37 25 22 22 TOTAL 134 158 165 156 141 Family Planning clinics reporting: At least one test in each year, 2002-2006: At least 100 tests in each year, 2002-2006: At least 200 tests in each year, 2002-2006: At least 500 tests in each year, 2002-2006: *CT, MA, ME, NH only; VT not included 61 45 29 13 Region I: Chlamydia positivity in women aged <26 years in family planning clinics, 2002-2006 10 9 Positivity (%) . 8 7 All FP FP >0 FP >99 FP >199 FP >499 6 5 4 3 2 *CT, MA, ME, NH VT not included 1 0 2002 2003 2004 *CT, MA, ME, NH only; VT not included Year 2005 2006 Region I: Tests Utilized by Family Planning Clinics Reporting >0 Tests Per Year 100 90 80 % of All Tests 70 60 GP PACE2 ABBOTT LCR BD SDA GP Aptima 50 40 30 20 10 0 2002 2003 *CT, MA, ME, NH only; VT not included 2004 2005 2006 Region I: Chlamydia positivity in women aged <26 years in family planning clinics reporting >99 tests per year, by test type, 2002-2006 10 9 Positivity (%) . 8 7 GP PACE2 ABBOTT LCR BD SDA GP APTIMA 6 5 4 3 2 Must have >50 positives in a single year of a single test type to be included. 1 0 2002 2003 2004 *CT, MA, ME, NH only; VT not included Year 2005 2006 Division of STD Prevention Priority: Increase Chlamydia Screening Among Women Aged <26 Years Vision of Success Imagine a national chlamydia partnership: Comprised of a wide array of engaged, energized partners from all sectors (private, public, non-profit, philanthropic) Focused on one overarching mission: high adherence to clinical guidance on annual chlamydia screening of sexually-active women ≤ 25 years old Performing a variety of interlocking, complementary activities that each is uniquely positioned to accomplish Efficiently applying assets toward the overarching mission ($, people, expertise, position, respect) Proactively identifying and addressing impacts of the growth of screening Summary No more CT supplements right now (but soon!) Interpretation of chlamydia data is difficult Chlamydia rates are decreasing? flat? increasing? PID rates appear to be decreasing Chlamydia screening coverage rates, while slowly improving, are still low Could analysis of continuously-reporting family planning clinics be a better way to analyze IPP data? Thanks! Division of STD Prevention, CDC Hillard Weinstock Deblina Datta Riduan Joesoef LaZetta Grier Rose Horsley Rob Nelson Lori Newman Jim Braxton Regional IPP Coordinators and Data Managers State and Local Health Departments